Brought to you by 
Ablexis LLC closes its $12mm Series A round
14 Feb 2017
Executive Summary
Ablexis LLC (MAbs) has raised $12mm through its Series A venture round led by Third Rock Ventures, which adds two board members. Pfizer Venture Investments also participated and adds a member to the board.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Transgenics
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ablexis LLC closes its $12mm Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice